Pro Share Advisors LLC Arcus Biosciences, Inc. Transaction History

Pro Share Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$14.83 - $20.18 $11,063 - $15,054	746 Added 7.39%	10,846 $204,000
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $135,643 - $198,263	10,100 New	10,100 $192,000
Q2 2022 Aug 01, 2022	SELL	$17.23 - $37.73 $144,904 - $317,309	-8,410 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$28.92 - $41.83 $39,475 - $57,097	-1,365 Reduced 13.96%	8,410 $266,000
Q4 2021 Feb 08, 2022	BUY	$31.38 - $48.47 $124,515 - $192,328	3,968 Added 68.33%	9,775 $396,000
Q3 2021 Nov 12, 2021	SELL	$26.93 - $37.68 $160,152 - $224,082	-5,947 Reduced 50.6%	5,807 $202,000
Q2 2021 Aug 13, 2021	BUY	$22.75 - $35.77 $11,215 - $17,634	493 Added 4.38%	11,754 $323,000
Q1 2021 May 14, 2021	BUY	$26.16 - $41.39 $50,305 - $79,592	1,923 Added 20.59%	11,261 $316,000
Q4 2020 Feb 09, 2021	BUY	$17.0 - $32.36 $158,746 - $302,177	9,338 New	9,338 $242,000

207

48.9M

173K

151K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.2B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.